Therefore, de novo FAs synthesis is upregulated in ovarian cancer, driven by increased ACLY, ACC, and FASN-mediated enzymatic activity, which promotes proliferation, metastasis, and chemoresistance. This evidence concerns the gene FASN and ovarian cancer.